Delving into the Latest Updates on Lanoconazole with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Lanoconazole (JP17/INN), Latoconazole

+ [5]

Target

fungal CYP51A1

Mechanism

fungal CYP51A1 inhibitors(Fungal CYP51A1 inhibitors)

Therapeutic Areas

Infectious DiseasesSkin and Musculoskeletal Diseases

Active Indication

Tinea PedisCandidiasisTinea+ [1]

Inactive Indication

Dermatitis, Seborrheic

Originator Organization

Maruho Co., Ltd.

Active Organization

Maruho Co., Ltd.

Nihon Nohyaku Co., Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

JP (01 Jul 1994),

CandidiasisTinea VersicolorTinea

Regulation-

Login to view timeline

Structure

Molecular FormulaC14H10ClN3S2

InChIKeyZRTQSJFIDWNVJW-WYMLVPIESA-N

CAS Registry101530-10-3

Fusarium are uncommon but important pathogenic organisms; they cause non-dermatophyte mould (NDM) onychomycosis. Patients typically respond poorly to treatment owing to Fusarium's native resistance to multiple antifungal drugs. However, epidemiological data for Fusarium onychomycosis are lacking in Taiwan. We retrospectively reviewed the data of 84 patients with positive Fusarium nail sample cultures at Chang Gung Memorial Hospital, Linkou Branch between 2014 and 2020. We aimed to investigate the clinical presentations, microscopic and pathological characteristics, antifungal susceptibility, and species diversity of Fusarium in patients with Fusarium onychomycosis. We enrolled 29 patients using the six-parameter criteria for NDM onychomycosis to determine the clinical significance of Fusarium in these patients. All isolates were subjected to species identification by sequences and molecular phylogeny. A total of 47 Fusarium strains belonging to 13 species in four different Fusarium species complexes (with Fusarium keratoplasticum predominating) were isolated from 29 patients. Six types of histopathology findings were specific to Fusarium onychomycosis, which may be useful for differentiating dermatophytes from NDMs. The results of drug susceptibility testing showed high variation among species complexes, and efinaconazole, lanoconazole, and luliconazole showed excellent in vitro activity for the most part. This study's primary limitation was its single-centre retrospective design. Our study showed a high diversity of Fusarium species in diseased nails. Fusarium onychomycosis has clinical and pathological features distinct from those of dermatophyte onychomycosis. Thus, careful diagnosis and proper pathogen identification are essential in the management of NDM onychomycosis caused by Fusarium sp.

01 Mar 2023·Mycoses

In vitro antifungal susceptibility profile of Iranian Fusarium isolates: Emphasising on the potent inhibitory effect of efinaconazole compared to other drugs

Article

Author: Haghani, Iman ; Katiraee, Farzad ; Shokohi, Tahereh ; Kachuei, Reza ; Faeli, Leila ; Nazeri, Mehdi ; Javidnia, Javad ; Salimi, Maryam ; Hedayati, Mohammad Taghi ; Badali, Hamid ; M.S. Al Hatmi, Abdullah ; Abastabar, Mahdi ; Khodavaisy, Sadegh ; Aghili, Seyed Reza ; Nosratabadi, Mohsen ; Mohammadi, Rasoul ; Zarrinfar, Hossein ; Javan‐Nikkhah, Mohammad ; Najafzadeh, Mohammad‐Javad

AbstractBackgroundFusarium species are opportunistic human pathogens that remarkably cause fungal infections ranging from superficial to fatal invasive disseminated infections. Fusarium species are notoriously resistant to the majority of antifungal agents.ObjectivesTherefore, detailed studies regarding in vitro susceptibility are required and may lead to a better prognosis of severe infections.MethodsWe evaluated 25 antifungal drugs in vitro against 282 clinical and environmental Fusarium isolates.ResultsFusarium species demonstrated high MICs/MECs values to the most commonly used antifungal drugs in clinical practice. The geometric mean (GM) MICs for luliconazole (0.004 μg/ml) and lanoconazole (0.012 μg/ml) were the lowest, followed by efinaconazole (0.98 μg/ml) and amphotericin B (1.04 μg/ml).ConclusionsEfinaconazole, a novel triazole, may be a promising candidate for the treatment of superficial Fusarium infections. Furthermore, the development of systemic formulations of these drugs as well as further in vitro and in vivo investigations could aid in the treatment of systemic fusariosis.

01 Nov 2022·Mycoses

Prevalence, genetic diversity and antifungal susceptibility profiles of F. fujikuroi, F. solani and Fusarium incarnatum‐equiseti species complexes from onychomycosis in north of Iran

Article

Author: Shokohi, Tahereh ; Hedayati, Mohammad Taghi ; Haghani, Iman ; Dalimi Asl, Abdolhossein ; Shams‐Ghahfarokhi, Masoomeh

AbstractOnychomycosis, a nail fungal infection, is normally caused by dermatophytes. However, yeasts and non‐dermatophyte moulds (NDM) are among pathogens that cause nail disease. Regarding, this study aimed to describe the molecular epidemiology of Fusarium onychomycosis in the North of Iran. Two hundred and fifty seven nail samples collected from the patients clinically suspected of onychomycosis were subjected to direct microscopy, calcofluor white staining and culture. Fusarium isolates were identified at a species level through determination of multi‐locus sequences for internal transcribed spacer and translation elongation factor 1 alpha. Based on the findings, Fusarium species were isolated from onychomycosis patients (n = 27). According to a previous partial genes analysis, the species in the recent study belonged to the members of F. fujikuroi species complex (n = 14), Fusarium incarnatum‐equiseti species complex (n = 1) and F. solani species complex (n = 12). In this study, F. proliferatum was the dominant Fusarium species collected from the samples. The correct identification of Fusarium species is essential regarding the increased prevalence of Fusarium onychomycosis and the inherent resistance of these agents to a wide spectrum of antifungals. The obtained results indicated variation in the epidemiology of Fusarium species isolated from onychomycosis. Moreover, the minimum inhibitory concentration (MIC) of luliconazole and lanoconazole was in the range of 0.001–1 μg/ml, with the geometric mean of MICs obtained at 0.0103 and 0.0343 μg/ml against Fusarium species, respectively. These findings can increase researchers' knowledge regarding diversity of species, distribution of onychomycosis and the choice of a proper treatment.

100 Deals associated with Lanoconazole

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D01092	-	D01A	-

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Tinea Pedis	JP	Nihon Nohyaku Co., Ltd.	16 May 2006
Candidiasis	JP	Maruho Co., Ltd.	01 Jul 1994
Tinea	JP	Maruho Co., Ltd.	01 Jul 1994
Tinea Versicolor	JP	Maruho Co., Ltd.	01 Jul 1994